VTVT News and Press, vTv Therapeutics Inc. From 12/20/21

Can-Fite BioPharma (NYSE:CANF) +71% liver cancer patient treated with can-Fite’s Namodenoson clears all cancer lesions under open label extension of phase II study. Society Pass Incorporated (NASDAQ:SOPA) +35% on being added to the Russell 2000 Index. Verso (NYSE:VRS) +3...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Unquestionably, stocks can make many small investors wealthy in just a few years. I believe that the best way to achieve that goal is not by buying the stocks that the vast majority of “big money” investors on...

Shares of vTv Therapeutics (NASDAQ:VTVT) rose 7% in after-hours trading after the company announced a restructuring that includes laying off nearly two-third of its employees. The company will focus on lead program TTP399, currently in phase 2 as an adjunct therapy to insulin for ty...

-Workforce reduction of 65% -Prioritization of lead program TTP399, a potentially transformative treatment for the reduction of hypoglycemic episodes in type 1 diabetes patients HIGH POINT, N.C., Dec. 06, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a...

vTv Therapeutics (NASDAQ:VTVT): Q3 GAAP EPS of -$0.02 beats by $0.05. Revenue of $3M (+29900.0% Y/Y) beats by $2.35M. Shares -1.33% PM. Press Release For further details see: vTv Therapeutics EPS beats by $0.05, beats on revenue

HIGH POINT, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2021, and provided an update on the progress of its clinical programs. “We plan to refocus vTv’s strateg...

vTv Therapeutics Announces Deepa Prasad as New President and CEO PR Newswire HIGH POINT, N.C. , Oct. 20, 2021 /PRNewswire/ -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered tre...

Study achieved primary endpoint of non-inferiority on measurement of key blood ketone levels Patients taking TTP399 reported no events of hypoglycemia, while four events of hypoglycemia were reported in the placebo arm Start-up activities for Phase 3 program ongoing with...

ZIVO Bioscience (NASDAQ:ZIVO) +81%. Meredith Corporation (NYSE:MDP) +16% on report IAC is in purchase talks Capricor Therapeutics (NASDAQ:CAPR) +26% on positive CAP-1002 data from mid-stage duchenne muscular dystrophy study vTv Therapeutics (NASDAQ:VTVT) +21% on ascending dose study...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! It’s the last day of the trading week and that we’re starting it off with a dive into Friday’s biggest pre-market stock movers! Source: f11photo/Shutterstock.com Earnings r...